According to World Health Organisation, In April 2019, World Health Organization (WHO) launched a malaria vaccine program in three African countries. The organization has launched this program intending to immunize 360,000 children worldwide to reduce the number of malarial sufferers.
Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-vaccines-market
Data Bridge Market Research analyses that the Asia-Pacific Vaccines Market is expected to grow at a CAGR of 9.4% from 2023 to 2030 and reach USD 18,031.69 million by 2030. The combination vaccines are projected to propel the market's growth as they protect against multiple diseases.
A high prevalence of chronic conditions such as flu, infectious, and viral diseases is accepted to drive the market growth
The prevalence of infectious diseases is increasing worldwide, and this has been seen that flu and bacterial infectious disease are surging rapidly. This increasing rate of infectious diseases has created the need for disease prevention which can be prevented by vaccination or immunization. As diseases are increasing significantly, there is an urgent need for mass vaccination. Mass vaccinations require a large amount of vaccine disease, which is expected to provide the vaccine market with lucrative growth.
For instances,
- According to World Health Organization (WHO), in 2020, the death count grew slower in India by 1.35 billion people 2020 than in the previous two years. India officially reported 148,738 COVID-19 deaths in 2020, with the tally jumping to 523,889 out of more than 43 million cumulative infections
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2017-2020)
|
|
Quantitative Units
|
Revenue in Million, Pricing in USD
|
|
Segments Covered
|
By Composition (Combination Vaccines and Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines), Kind (Routine Vaccine, Recommended Vaccine, and Required Vaccine), Age of Administration (Pediatric Vaccine and Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, and Others), Route of Administration (Injectable, Oral, and Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, and Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and the Rest of Asia-Pacific
|
|
Market Players Covered
|
Bharat Biotech, Biological E Limited, Bio Farma, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, and BAXTER VACCINES (a subsidiary of Baxter), among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, value and supply chain analysis, business strategy excellence, the strength of product portfolio, technological trends, case studies, and regulatory framework.
|
Segment Analysis:
Asia-Pacific vaccines market is categorized into eight notable segments based on the composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel.
- On the basis of composition, the Asia-Pacific vaccines market is segmented into combination vaccines and monovaccines.
In 2023, the combination vaccines composition segment is expected to dominate the Asia-Pacific vaccine market.
In 2023, the combination vaccines segment is expected to dominate the market by providing fewer shots, less pain and discomfort, and on-time protection. The combination vaccine segment is expected to reach the highest CAGR of 9.7% from 2023 to 2030.
- On the basis of type, the Asia-Pacific vaccines market is segmented into subunit, recombinant, polysaccharide, and conjugate vaccines, live-attenuated vaccines, inactivated vaccines, toxoid vaccines, and DNA vaccines. In 2023, the subunit, recombinant, polysaccharide, and conjugate vaccines segment is expected to dominate the market with 66.92% market share because they give a very strong immune response that's targeted to key parts of the germs
- On the basis of kind, the Asia-Pacific vaccines market is segmented into routine vaccine, recommended vaccine, and required vaccine. In 2023, the routine vaccine segment is expected to dominate the market with a 70.43 % market share because it could reduce infectious disease burden in early childhood and thereby help break the intergenerational cycle of poverty, poor health, and low income
- On the basis of age of administration, the Asia-Pacific vaccines market is segmented into pediatric vaccine and adult vaccine. In 2023, the pediatric vaccine segment is expected to dominate the market with a 61.88% market share because of increasing government initiatives for immunization, the rising prevalence of diseases, and the high demand for vaccines for infants
- On the basis of diseases, the Asia-Pacific vaccines market is segmented into pneumococcal disease, measles, mumps & varicella, DPT, hepatitis, influenza, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and others. In 2023, the pneumococcal disease segment is expected to dominate the market with 23.05%market share because of rising pneumonia infection rates in infants and adults and increasing immunization programs for the betterment of the population
- On the basis of route of administration, the Asia-Pacific vaccines market is segmented into injectable, oral, and nasal. In 2023, the injectable segment is expected to dominate the market with an 82.43% market share because most vaccines are administered through the parenteral route of administration. Moreover, injectable provides long-term effect in the form of sustained or controlled release manner
- On the basis of end user, the Asia-Pacific vaccines market is segmented into community hospitals, hospitals, specialty centers, clinics, and others.
In 2023, the community hospitals segment is projected to hold the largest share of end user segment in the Asia-Pacific vaccines market
In 2023, the community hospitals segment holds the maximum market share as more patients prefer to visit hospitals for different vaccination. The community hospital segment is growing with a CAGR of 10.2 % in the forecast period of 2023 to 2030.
- On the basis of distribution channel, the Asia-Pacific vaccines market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2023, the hospital pharmacy segment is expected to dominate the market with a 66.75% market share because vaccines are directly procured from the company distributors as well as the majority of the population seeks immunization from the hospitals
Major Players
Data Bridge Market Research recognizes the following companies as the major Asia-Pacific vaccines market players in global Asia-Pacific vaccines market are Bharat Biotech, Biological E Limited, Bio Farma, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, and BAXTER VACCINES (a subsidiary of Baxter), among others.
Market Development
- In January 2023, Serum Institute of India Pvt. Ltd. announced the launch of the first made-in-India qHPV vaccine, "CERVAVAC". It is a vaccine against human papillomavirus
- In December 2022, Biological E. Limited announced that its 14-valent pediatric Pneumococcal Conjugate Vaccine received approval from the Drugs Controller General of India (DGCI) for manufacture and commercialization in India
- In November 2020, Seqirus (A Subsidiary of CSL Limited) announced the opening a new vaccine manufacturing facility in Australia. The company has decided to manufacture a new facility by investing an amount of USD 800 million to accelerate the manufacturing of the Q- Fever vaccine and influenza vaccines. This initiative helped the company to attain lucrative growth in the vaccines market
- In November 2020, Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.) signed an agreement to acquire OncoImmune, a clinical-stage biopharmaceutical company. The OncoImmune is highly focused on the development of COVID 19 treatment option
- In October 2020, Takeda Pharmaceutical Company Limited went under a partnership with Moderna and Japan government to supply the COVID-19 vaccine. As per the partnership agreement, the company will supply 50 million doses of mRNA-1273 in Japan. This partnership helped the company to continue leveraging the research and developmental activities
Regional Analysis
Geographically, the countries covered in the Asia-Pacific vaccines market report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
Japan is the dominant region in the Asia-Pacific vaccines market during the forecast period 2023 - 2030
In 2023, Japan dominated the Asia-Pacific vaccines market owing to the higher level of investments by U.S. manufacturers and the increasing prevalence of chronic disorders in the region. Japan will continue to dominate the Asia-Pacific vaccines market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and the launch of new products in this region. Additionally, the increasing number of disorders and autoimmune diseases is expected further to enhance this region's market's growth rate.
Japan is estimated to be the fastest-growing country in the Asia-Pacific vaccines market for the forecast period 2023 - 2030
Japan is expected to grow during the forecast period due to the presence of major market players and the rapid development of medical facilities in emerging economies in this region. In addition, rising awareness about Asia-Pacific vaccines and increasing government support are expected to propel the market's growth rate in this region.
COVID-19 Impact Analysis
The outbreak of COVID-19 largely impacted the healthcare industry. The Asia-Pacific vaccines market was, however, adversely affected by it. The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak led to the emergence of various challenges, such as the halt of various operations, canceled or postponed elective vaccination, stifling business growth, suspensions of new developments, and even increasing disorder in COVID-19 medical care providers, further limiting the industry's expansion. As the admission of COVID-19 patients in hospitals increased, numerous vaccination was canceled or postponed to reserve patient care staff for COVID-19 patient care. Developing and implementing contingency plans is crucial for business operations and key imported raw materials.
On the brighter side, there has been a decline in COVID-19 patients worldwide, which will result in increased vaccination. Moreover, the restrictions and measures are likely to relax, which will help the market to witness a slight increment, as the manufacturers focus on various developments and innovations, market trends, and other expansion strategies. Thus, the Asia-Pacific vaccines market will grow at an accelerated pace post-COVID-19.
